




Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Attorney Docket No. 06132/075002 Serial No. 10/715,868 Applicant Juan Arroyo Filing Date November 17, 2003 Group 1642 IDS Filed September 10, 2004				
U.S. PATENTS						
Examiner's Initials	Patent Number or Publication Number	Issue Date or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
ME	6,136,561	10/24/00	Ivy et al.	435	69.3	
	6,184,024 B1	02/06/01	Lai et al.	435	235.1	
	6,416,763 B1	07/09/02	McDonell et al.	424	218.1	
	6,696,281 B1	02/24/04	Chambers et al.	435	235.1	
ME	2003/0129201 A1	07/10/03	Monath et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
ME	WO 93/06214	04/01/93	WIPO			
	WO 98/37911	09/03/98	WIPO			
	WO 01/39802 A1	06/07/01	WIPO			
ME	WO 03/063725 A2	08/07/03	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
ME	Arroyo et al., "Molecular Basis for Attenuation of Neurovirulence of a Yellow Fever Virus/Japanese Encephalitis Virus Chimera Vaccine (ChimeriVax-JE)," J. Virol. 75:934-942, 2001.					
	Arroyo et al., "Yellow Fever Vector Live-Virus Vaccines: West Nile Virus Vaccine Development," Trends in Molecular Medicine 7:350-354, 2001.					
	Bray et al., "Construction of Intertypic Chimeric Dengue Viruses by Substitution of Structural Protein Genes," Proc. Natl. Acad. U.S.A. 88:10342-10346, 1991.					
	Caufour et al., "Construction, Characterization and Immunogenicity of Recombinant Yellow Fever 17D-Dengue Type 2 Viruses," Virus Research 1-14, 2001.					
	Chambers et al., "Mutagenesis of the Yellow Fever Virus NS2B/3 Cleavage Site: Determinants of Cleavage Site Specificity and Effects on Polyprotein Processing and Viral Replication," J. Virol. 69:1600-1605, 1995.					
ME	Chambers et al., "Vaccine Development Against Dengue and Japanese Encephalitis: Report of a World Health Organization Meeting," Vaccine 15:1494-1502, 1997.					
EXAMINER <i>M. [Signature]</i>			DATE CONSIDERED <i>10/12/04</i>			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						


SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Attorney Docket No. 06132/075002 Serial No. 10/715,868 Applicant Juan Arroyo Filing Date November 17, 2003 Group 1642 IDS Filed September 10, 2004
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)		
<i>MRJ</i>	Chambers et al., "Yellow Fever/Japanese Encephalitis Chimeric Viruses: Construction and Biological Properties," J. Virol. 73:3095-3101, 1999.	
	Coia et al., "Nucleotide and Complete Amino Acid Sequences of Kunjin Virus: Definitive Gene Order and Characteristics of the Virus-Specified Proteins," J. Gen. Virol. 69:1-21, 1988.	
	Davis et al., "West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses In Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorbent Assays," J. Virology 75:4040-4047, 2001.	
	Duarte dos Santos et al., "Complete Nucleotide Sequence of Yellow Fever Virus Vaccine Strains 17DD and 17D-213," Virus Research 35:35-41, 1995.	
	Galler et al., "Genetic Variability Among Yellow Fever Virus 17D Substrains," Vaccine 16:1-5, 1998.	
	Galler et al., "The Yellow Fever 17D Vaccine Virus: Molecular Basis of Viral Attenuation and its Use as an Expression Vector," Braz. J. Biol. Res. 30:157-168, 1997.	
	Guirakhoo et al., "Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine," J. Virol. 75:7290-7304, 2001.	
	Guirakhoo et al., "Immunogenicity, Genetic Stability, and Protective Efficacy of a Recombinant, Chimeric Yellow Fever-Japanese Encephalitis Virus (ChimeriVax-JE) as a Live, Attenuated Vaccine Candidate Against Japanese Encephalitis," Virol. 257:363-372, 1999.	
	Lai et al., "Evaluation of Molecular Strategies to Develop a Live Dengue Vaccine," Clin. Diag. Virol. 10:173-179, 1998.	
	Mandl et al., "Sequence of the Genes Encoding the Structural Proteins of the Low-Virulence Tick-Borne Flaviviruses Langat TP21 and Yelantsev," Virol. 185:891-895, 1991.	
	Mandl et al., "Complete Genomic Sequence of Powassan Virus: Evaluation of Genetic Elements in Tick-Borne Versus Mosquito-Borne Flaviviruses," Virol. 194:173-184, 1993.	
	Marchevsky et al., "Phenotypic Analysis of Yellow Fever Virus Derived from Complementary DNA," American J. Tropical Medicine & Hygiene 52:75-80, 1995.	
<i>✓</i>	Monath et al., "Chimeric Yellow Fever Virus 17D-Japanese Encephalitis Virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing in Rhesus Monkeys," J. Virol. 74:1742-1751, 2000.	
<i>MRJ</i>	Monath et al., "West Nile Virus Vaccine," Current Drug Targets-Infectious Disorders 1:1-14, 2001.	
EXAMINER	<i>M. J. [Signature]</i>	DATE CONSIDERED <i>10/12/04</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.		

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Attorney Docket No. 06132/075002 Serial No. 10/715,868 Applicant Juan Arroyo Filing Date November 17, 2003 Group 1642 IDS Filed September 10, 2004
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)		
MF)	Pietnev et al., "Construction and Characterization of Chimeric Tick-Borne Encephalitis/Dengue Type 4 Viruses," Proc. Natl. Acad. Sci. U.S.A. 89:10532-10536, 1992.	
	Rice et al., "Transcription of Infectious Yellow Fever RNA from Full-Length cDNA Templates Produced by In Vitro Ligation," The New Biologist 1:285-296, 1989.	
	Shiu et al., "Genomic Sequence of the Structural Proteins of Louping Ill Virus: Comparative Analysis with Tick-Borne Encephalitis Virus," Virology 180:411-415, 1991.	
	Stocks et al., "Signal Peptidase Cleavage at the Flavivirus C-prM Junction: Dependence on the Viral NS2B-3 Protease for Efficient Processing Requires Determinants in C, the Signal Peptide, and prM," J. Virol. 72:2141-2149, 1998.	
	Van Der Most et al., "Chimeric Yellow Fever/Dengue Virus as a Candidate Dengue Vaccine: Quantitation of the Dengue Virus-Specific CD8 T-Cell Response," J. Virol. 74:8094-8101, 2000.	
MF)	Venugopal et al., "Towards a New Generation of Flavivirus Vaccines," Vaccines 12:966-975, 1994.	
EXAMINER <i>M. M. Lopez</i>		DATE CONSIDERED <i>10/14/06</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.		

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	06132/075002
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p>		Serial No.	10/715,868		
		Applicant	Juan Arroyo et al.		
		Filing Date	November 17, 2003		
		Group	1648		
		IDS Filed	June 15, 2006		

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
<i>MKS</i>	Johnson et al., "Growth Characteristics of the Veterinary Vaccine Candidate ChimerVax-West Nile (WN) Virus in Aedes and Culex Mosquitoes," Med. Vet. Entomol. 17:235-243, 2003.					
<i>MKS</i>	Monath, "Prospects for Development of a Vaccine Against the West Nile Virus," Ann. NY Acad. Sci. 951:1-12, 2001.					
<i>MKS</i>	Monath et al., "Clinical Proof of Principle for ChimerVax: Recombinant Live, Attenuated Vaccines Against Flavivirus Infections," Vaccine 20:1004-1018, 2002.					
<i>MKS</i>	Monath et al., "West Nile Virus Vaccine," Curr. Drug Targets Infect. Disord. 1:37-50, 2001.					
<i>MKS</i>	Tesh et al., "Efficacy of Killed Virus Vaccine, Live Attenuated Chimeric Virus Vaccine, and Passive Immunization for Prevention of West Nile Virus Encephalitis in Hamster Model," Emerg. Infect. Dis. 8:1392-1397, 2002.					
<i>MKS</i>	Supplementary European Search Report from Corresponding European Application No. EP 03 78 3570.					

EXAMINER <i>MKS</i>	DATE CONSIDERED <i>1/21/06</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Attorney Docket No. 06132/075002 Serial No. 10/715,868 Applicant Arroyo et al. Filing Date November 17, 2003 Group 1648 IDS Filed August 2, 2006
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	-----------------------------------------------------------------------------------------------------------------------------------------------------------------

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
RES	Allison et al., "Mapping of Functional Elements in the Stem-Anchored Region of Tick-Borne Encephalitis Virus Envelope Protein E," J. Virol. 73:5605-5612, 1999.					
/	Allison et al., "Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E," J. Virol. 75:4268-4275, 2001.					
/	Lee et al., "Mechanism of Virulence Attenuation of Glycosaminoglycan-Binding Variants of Japanese Encephalitis Virus and Murray Valley Encephalitis Virus," 76:4901-4911, 2002.					
/	Mandl et al., "Adaptation of Tick-Borne Encephalitis Virus to BHK-21 Cells Results in the Formation of Multiple Heparan Sulfate Binding Sites in the Envelope Protein and Attenuation In Vivo," J. Virol. 75:5627-5637, 2001.					
APS	Mandl et al., "Attenuation of Tick-Borne Encephalitis Virus by Structure-Based Site-Specific Mutagenesis of a Putative Flavivirus Receptor Binding Site," J. Virol. 74:9601-9609, 2000.					

EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>10/01/06</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	